Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.80 |
| ▸ | ARG2 | P78540 | 4/20 | 0.70 |
| ▸ | ARG1 | P05089 | 3/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.62 |
| ▸ | GRM8 | O00222 | 1/20 | 0.62 |
| ▸ | GRM6 | O15303 | 1/20 | 0.62 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.62 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.62 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.62 |
| ▸ | GRM5 | P41594 | 1/20 | 0.62 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.62 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.62 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.62 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.62 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.62 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.62 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.62 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.62 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.62 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3239635 | 1.00 | GSR (0.80) | GSRARG2ARG1CYP1A2GRM8 | |
| SCHEMBL29268443 | 1.00 | GSR (0.80) | GSRARG2ARG1CYP1A2GRM8 | |
| SCHEMBL293201 | 1.00 | GSR (0.80) | GSRARG2ARG1CYP1A2GRM8 | |
| SCHEMBL8893420 | 0.97 | GSR (0.76) | GSRARG2ARG1CYP1A2GRM8 | |
| Hydrochloric Acid SCHEMBL20541043 | 0.97 | GSR (0.76) | GSRARG2ARG1CYP1A2GRM8 | |
| SCHEMBL8894128 | 0.97 | GSR (0.76) | GSRARG2ARG1CYP1A2GRM8 | |
| Hydrochloric Acid SCHEMBL20541045 | 0.97 | GSR (0.76) | GSRARG2ARG1CYP1A2GRM8 | |
| Hydrochloric Acid SCHEMBL20541044 | 0.97 | GSR (0.76) | GSRARG2ARG1CYP1A2GRM8 | |
| SCHEMBL4848672 | 0.97 | GSR (0.76) | GSRARG2ARG1CYP1A2GRM8 | |
| SCHEMBL9829771 | 0.97 | GSR (0.76) | GSRARG2ARG1CYP1A2GRM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117586376-A | Long-acting insulin compound | 成都奥达生物科技有限公司 | 2024-02-23 | — | — | CN | disclosed |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| CN-114075276-A | Long-acting relaxin 2 analogue | 成都奥达生物科技有限公司 | 2022-02-22 | — | — | CN | disclosed |
| CN-114075275-A | Long-acting insulin analogue | 成都奥达生物科技有限公司 | 2022-02-22 | — | — | CN | disclosed |
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-07-20 | — | — | US | disclosed |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2021-04-01 | — | — | US | disclosed |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RAPAFUSYN PHARMACEUTICALS, INC. | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, FKBP14, MTOR | GSR 4015/4885ARG2 1105/4885ARG1 2742/4885 |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | GSR 4015/4885ARG2 1105/4885ARG1 2742/4885 |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | GSR 4015/4885ARG2 1105/4885ARG1 2742/4885 |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | GSR 4015/4885ARG2 1105/4885ARG1 2742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.